7-year-old receives experimental drug at St. Jude - Action News 5 - Memphis, Tennessee

7-year-old receives experimental drug at St. Jude

Posted: Updated:
Hardy is the first of 20 patients who will test the drug during a pilot study. Hardy is the first of 20 patients who will test the drug during a pilot study.
The bio-drug maker Chimerix Inc., based in Raleigh, NC, provided the experimental drug, which is called brincidofovir. The bio-drug maker Chimerix Inc., based in Raleigh, NC, provided the experimental drug, which is called brincidofovir.
MEMPHIS, TN -

(WMC-TV) - Josh Hardy, a 7-year-old boy who garnered national attention through his need for an experimental drug, received that drug at St. Jude Children's Research Hospital.

Hardy is fighting a virus he received after a bone marrow transplant. During a teleconference Thursday, doctors announced that he received the drug just after 9 p.m. Wednesday. Doctors say he is still very sick and has a long road ahead, but the drug is offering everyone a bit of hope.

"We really don't care what excuses there are. They have something that can help our son," said mother Aimee Hardy Monday.

The bio-drug maker Chimerix Inc., based in Raleigh, NC, provided the experimental drug, which is called brincidofovir.

Hardy is the first of 20 patients who will test the drug during a pilot study.

"Battling this viral infection is one of many components of Josh's treatment," said Dr. Williams Evans.

The drug helps treat that viral infection, and doctors say the oral version he is taking is less hard on his kidneys.

"He has been in the ICU, for several weeks following a bone marrow transplant and is facing critical, complex medical problems," said Dr. Larry Kun, clinical director.

Wednesday night Josh received the drug, and doctors say he is in good spirits. They said Thursday he may even get to walk around outside and enjoy the weather.

Meantime, his parents remain by his side updating Action News 5 via phone that his spirits are high.

Doctors are grateful for the support from drug maker Chimerix. They hope it paves the way for others.

"He is a very sick little boy. This is a marathon, not a sprint in terms of providing his treatment going forward," said Evans.

Doctors says Josh is tolerating the drug, but it will take time to figure out exactly how it is working.

Get the latest from Action News 5 anytime: iPhone | iPad | Android | SMS Alerts | Email Alerts | Facebook | Twitter | Instagram

Copyright 2014 WMC-TV. All rights reserved.
Powered by WorldNow